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Abstract 
Toxic epidermal necrolysis (TEN), also known as Lyell’s syndrome, is a life-threatening 
disease with common development of large wounds. Thus, affected patients are usually 
treated in specialized centers. Herein, we present a case of TEN in a patient infected with 
human immunodeficiency virus with the additional, unexpected diagnosis of dengue 
fever. In this context, we discuss cause, diagnosis, pathology, and treatment of TEN and 
highlight the role of rare and unexpected findings, as in this case an additional tropical 
virus infection. We underpin the importance of an interdisciplinary approach involving 
dermatologists, ophthalmologists, intensive care physicians, burn specialists and various 
other departments and emphasize the challenge of TEN treatment, especially if rare 
pathological findings occur. 
 
Introduction 
Toxic epidermal necrolysis (TEN) is an extreme, rapidly-evolving skin disorder, which 
is characterized by extensive painful cutaneous exfoliation. Also known as Lyell’s 
syndrome, this dermatological condition can be life-threatening [1]. The major cause of 
TEN is medication hypersensitivity, thus the most effective treatment is the immediate 
withdrawal of the causative agent [2]. Due to the common development of large wounds 
with high risk of infection and resulting sepsis, patients suffering from TEN should be  
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treated in specialized centers. Wound treatment regimens and the role of special wound 
dressings are still under current debate [3, 4]. Unexpected comorbidities and pathological 
findings may complicate the clinical picture, making management even more challenging 
for burn unit teams. 
In this context, we present a case of TEN in a patient infected with human 
immunodeficiency virus (HIV) with the additional, unexpected diagnosis of dengue fever 
(DF). This case report highlights the importance of clinical vigilance on the part of 
intensive care staff to pursue additional diagnostic considerations when patient symptoms 
(e.g. fever) cannot be explained by the routine causes. 
Case Report 
A 34-year-old African female came to the emergency room (ER) of the RWTH Aachen University, 
Aachen, Germany, reporting fever up to 40°C for a week and new painful blisters over her back and 
right arm with a rash over her whole body. She had a history of HIV infection for 10 years (CD4+/CD8+ 
ratio: 0.1; CD4+ count: 208) treated during the last year with Combivir (300 mg lamivudine and 150 mg 
zidovudine p.o., 2 per day) and Kaletra (100 mg lopinavir and 25 mg ritonavir p.o., 1 per day). After 
trying supportive care (vitamins and micronutrients) and pain relieving medications (500 mg 
acetylsalicylic acid p.o., 2 per day; 1 g acetaminophen p.o., 4 per day) for 5 days, the patient consulted a 
general practitioner. Concerned about a bacterial infection, he empirically prescribed cefuroxime (250 
mg p.o., 2 per day) and azithromycin (500 mg p.o., 1 per day) as well as fluconazole (50 mg p.o., 1 per 
day). A rash began on her trunk the day after starting antimicrobials. It became worse the following day, 
expanding over the whole body with painful blisters on her back and right arm. She also developed 
higher fevers and malaise. 
On examination by the internal ER doctor, the patient (weight: 85 kg, BMI: 29.4) was conscious and 
oriented. She was normotensive (blood pressure 120/65) with sinus tachycardia (heart rate 124/min). 
Further examination revealed dry lips and tongue, suggesting dehydration. She had conjunctival 
injection, but her chest and abdominal examination revealed no abnormalities. The blisters ranged 
between 0.5 and 4 cm (fig. 1) and covered her trunk, abdomen, upper back, neck, and both arms (right 
more pronounced than left), covering about 45% of the total body surface area. 
The ER doctor, suspecting TEN, called for the dermatologist and the burn surgeon for consultation. 
Confirming the presumptive diagnosis, the patient was transferred to the intensive care unit (ICU) for 
optimal treatment and further wound care. 
On admission to the ICU, central venous access was secured and fluid resuscitation was initiated 
with lactated Ringer’s solution. In addition to standard monitoring, central venous and arterial 
pressures were measured. The former antimicrobial therapy was immediately stopped. Laboratory 
markers revealed an increase of CRP (201 mg/l) but not leucocytes. The serum protein (104 g/l) and the 
LDH concentration (518 U/ml) were elevated. Besides this, no pathological findings occurred. A chest 
X-ray showed no pathological findings. Furthermore, cultures of blood, urine and wound were 
unrevealing. The blisters were disinfected with Octenisept (0.1 g octenidindihydrochlorid, 2.0 g 
phenoxyethanol per 100 ml), and covered with Acticoat
TM (silver antibacterial protection; 
Smith&Nephew, London, United Kingdom) and dry sterile gauzes. The patient remained conscious and 
vitally stable throughout the inpatient course. Dressings with Acticoat were changes every 3 days (fig. 
2). The patient continued to have intermittent high fever up to 40°C. Since all bacterial and fungal 
screenings remained negative, the focus of infection was unclear. Upon consultation with the infectious 
disease service, empiric antibiotic and antifungal medications were started with Avalox (400 mg 
moxifloxacin i.v., 1 per day) and Ecalta (100 mg anidulafungin i.v., 1 per day). The former anti-viral 
HIV therapy was continued without changes. 
Three days after admission to the hospital, polymerase chain reaction testing for viruses revealed 
DNA in serum of dengue virus. The patient had initially denied any recent travel, but after further 
questioning she admitted a recent visit to Kenya. Antimicrobials were stopped and fever began to 
decrease slowly on the fifth day of inpatient treatment. Wounds recovered well under careful treatment  
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with Acticoat. After 18 days of inpatient treatment, the patient was able to be discharged home. Follow-
up examination in our outpatient center revealed no secondary deficits.  
Discussion 
The cutaneous findings of TEN result in acute macular erythematous rash with bulla, 
and red macules with central blistering [4]. Usually, the lesions rapidly exhibit the 
Nikolsky’s sign (epidermal separation induced by gentle lateral pressure of the skin 
surface) which facilitates the diagnosis [5]. Besides affecting the mucosal and ocular 
surface, the lesions can become extremely extensive until a complete loss of epidermis 
within 24 h. Thus, TEN is associated with significant morbidity, including 
thermoregulatory disturbance and dehydration, and leads to lung, renal, liver and heart 
failure in severe cases [6]. Mortality is approximately 40%, but it depends on co-morbidity 
and individual factors [7]. The risk of mortality can be assessed by a specific severity 
evaluation system, also known as the Severity-of-Illness Score for Toxic Epidermal 
Necrolysis or SCORTEN [6]. In our specific case the SCORTEN score was calculated to be 
two. 
In the majority of the cases a drug reaction is the cause of TEN. Most commonly 
involved are several antibiotics (sulfonamide, tetracycline, quinolones, β-lactam), 
anticonvulsants (phenytoin, carbamazepine), nonsteroidal anti-inflammatory drugs or 
alluporinol [4]. To date, research has failed to demonstrate the mechanism by which 
exposure to a particular drug can lead to TEN pathology. Alternately, a combination of 
different drugs rather than a single drug may be the possible cause [4].  
In the presented case, however, we presume that the TEN was a reaction to  
cefuroxime, azithromycin or the combination of both medications prescribed by the 
general practitioner. 
But besides drugs, certain individuals have an enhanced risk for TEN. This includes 
bone marrow transplant patients [8], individuals with systemic lupus erythematosus, only 
rarely persons with exposure to certain chemicals [9], and individuals receiving different 
vaccinations [4] as well as persons with HIV-1 infection [10]. In our case, the patient was 
HIV positive, which could contribute to the occurrence of TEN. However, the possible 
involvement and contribution of an infection with the dengue virus and resulting DF is 
unknown. 
Transmitted by the Aedes aegypti mosquito, DF is a disease belonging to the family 
Flaviviridae, genus Flavivirus [11]. DF, as well as the more severe dengue hemorrhagic 
fever, is caused by four closely related viruses called dengue 1 through 4 (DENV 1–4) 
[12]. Dengue viruses are maintained in primitive rainforest cycles involving lower 
primates and mosquitoes in Asia and West Africa [13]. However, DEN viruses can be 
transmitted in an urban cycle between humans and the highly domesticated mosquito 
[14]. Indeed, the A. aegypti proves to be a very efficient epidemic vector as DEN viruses 
are the only arboviruses that have fully adapted to humans and are maintained in large 
urban centers of the tropics [15]. Dengue virus infection in humans can cause a spectrum 
of illness ranging from occult infection to severe hemorrhagic disease [15]. Fortunately, 
the percentage of fatal cases is about only 5%, thus the majority of infections present an 
abrupt onset of mild febrile illness [15], which applies well to our presented case.  
Case Rep Dermatol 2010;2:189–194 
DOI: 10.1159/000322963 
Published online: 
December 7, 2010 






However, because of the risk of a hemorrhagic fever, these patients have to be monitored 
carefully. 
DF is a very old disease and has historically caused major public health problems due 
to wide epidemics during its starting period in the 17th until the early 20th century [14]. 
The initial geographic expansion of DF was closely tied to the global spread of A. aegypti 
mosquitoes from Africa to other parts, but always remained in tropical regions [16]. Thus, 
infection in humans in temperate zones such as Europe is usually acquired by exposure to 
mosquitoes in equivalent tropical regions. Although the diagnosis of DF in Europe is rare, 
it should be taken under consideration amongst febrile returning travelers. 
Intriguingly, in the past 30 years the DEN viruses have spread between countries and 
continents in the tropical regions [15], which increased its frequency in the Pacific 
Islands, South America and Asia. But still, the infection of DEN virus is limited to tropical 
regions with occurrence of A. aegypti, and thus making its appearance in temperate zones 
very rare. 
However, this case report not only presents the illness of TEN, but it demonstrates that 
staff in specialized centers has to be well aware of improbable findings as, for example, an 
uncommon virus infection. 
Thus, it is important that treatment of TEN always includes an interdisciplinary 
approach involving dermatologists, ophthalmologists, intensive care physicians, burn 
specialists, and beyond this, various other departments. To the best of our knowledge, we 
present for the first time a case of TEN with DF in a European ICU. We emphasize that 
TEN can be a complex and diverse illness resulting in total organ failure and shock in 
severe cases, and it is always challenging for an intensive care team, especially if rare 
pathological findings occur.  
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Fig. 2. Progressive wound healing during treatment with Acticoat
TM. 
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